As a highly prolific center for cancer research, Roswell Park Cancer Institute has long been a source of important new products and processes for use in the fight against cancer. RPCI maintains over 100 active patents, and submits an average of 20 patent applications annually. The revenue generated by patents and licensing agreements places the Institute’s Technology Transfer Office among the top 25 offices of its kind in the nation.

Below are some Commercialization news stories that may be of interest.  You can browse more videos in the Multi-Media News Room.

Click here to learn how Photodynamic Therapy is FDA approved to treat Barrett's Esophagus.

Click here to learn how Photodynamic Therapy offers a non-surgical way to treat skin cancer.

Commmercial Development serves three principal functions:

1. Facilitating the process of applying for patents, trademarks, and copyrights for materials produced at RPCI;
2. Informing the business community about licensing opportunities for products and technologies developed at RPCI; and
3. Promoting the commercialization of products and technologies developed at RPCI, either through license agreements, or by supporting the creation of spin-off companies that emerge to develop products and processes originating at RPCI.

RPCI recently launched new businesses: AndroBioSys and Empire Genomics.

AndroBioSys will commercialize a new cancer drug-screening in vivo model that is derived from the work of Dr. James Mohler and Dr. Gary Smith in the Department of Urologic Oncology.	Empire Genomics established a commercial laboratory in the Center of Excellence to provide services in the area of human genetic aberrations. It is run by Dr. Norma Nowak in the Department of Cancer Prevention & Control.